After breaking to higher ground a week ago on enormous volume, shares of ARDELYX INC - NASDAQ: ARDX find themselves in constructive consolidation mode digesting the recent run on lower volume as we can observe from the Daily chart above.
With the stock trading well above its 20/50 and 200 DMA's on the Daily timeframe, the short-term technical posture of ARDX...
05:13 Piper still sees 'substantial upside' in Ardelyx despite last week's rally
Piper Jaffray analyst Christopher Raymond says he still expects "substantial upside" in shares of Ardelyx even after last week's 43% move. While Amplify's more "real world" representation assuaged the key investor concern around tenapanor's adverse event-related discontinuations,...
Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of renal diseases. It focuses on the formulation of programs directed toward treating gastrointestinal and irritable bowel syndrome with constipation. Its product portfolio includes tenapanor, which is an experimental...
Large insto bets have been placed at this $4 level. My feeling is this price level will hold, in which case it is only a matter of time before it breaks out of this descending chanel. An impulsive move up is then likely.
ARDX forming a nice fallen angel base, with higher lows. Twinges moneyflow showing strong divergence.
We think it has good upside potential.
* Trade Criteria *
Date First Found- August 22, 2017
Pattern/Why- Fallen angel pattern
Entry Target Criteria- Break of $5.53
Exit Target Criteria- $5.97
Stop Loss Criteria- $5.17
Please check back for Trade updates....
ARDX seems forming a nice fallen angel formation. It had huge of insider buying. We think it has very good upside potential.
* Trade Criteria *
Date First Found- June 22, 2017
Pattern/Why- Fallen angel pattern
Entry Target Criteria- Break of $5.17
Exit Target Criteria- $7.23
Stop Loss Criteria- $4.73
Please check back for Trade updates. (Note: Trade...
Some insider buying this past week. Hard to tell other than the minor increase of SMA50 (Red SMA). RSI gradually increasing, OBV still strong. MACD making higher lows.
Conservative approach: Before dipping in, at least wait till SMA50 (Red MA) begins a positive slope. Otherwise you may end up trying to 'catch a falling knife' with others.
Obey your rules.
Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of renal diseases. It focuses on the formulation of programs directed toward treating gastrointestinal and irritable bowel syndrome with constipations. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
ARDX
